Insmed company profile
Company profile
Insmed has 1,664 employees and is headquartered in Bridgewater, United States.
Based in Bridgewater, New Jersey, and founded in 1988, Insmed focuses on treatments for rare and serious lung and other diseases. Its marketed product ARIKAYCE targets refractory nontuberculous mycobacterial lung infections. The pipeline includes brensocatib, a DPP1 inhibitor in phase 3 for bronchiectasis, an inhaled treprostinil palmitil formulation for pulmonary hypertension, and INS1201, a gene replacement therapy for Duchenne muscular dystrophy in phase 1. Research programs cover gene therapy and protein engineering. Its patients and markets are in the United States, Europe, Japan and other countries.
In the fiscal year ended December 2025, Insmed reported revenue of 606.4 million US dollars, up 66.7% from the previous year, and a net loss of 1.3 billion US dollars. The United States accounted for 74.7% of revenue and non-US markets for 25.3%. The company had 1,664 employees, and its headquarters are in Bridgewater.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 700 US Highway 202/206, 08807, Bridgewater
- Employees
- 1,664
- Chief executive
- William Lewis
- Founded
- 1988
- Fiscal year
- January - December
- Listing
- INSM · NASDAQ
- Currency
- USD
- ISIN
- US4576693075
- Website
- insmed.com
Insmed and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| InsmedINSM | United States | $26.96B | 1,664 | -41.7% | — |
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
| IncyteINCY | United States | $24.36B | 2,844 | 32.2% | 61.0 |
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
